{
    "nctId": "NCT06259162",
    "briefTitle": "LAG3 Expression in Triple Negative Breast Cancer",
    "officialTitle": "The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer, Immune Checkpoint Inhibitor",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SCREENING",
    "enrollmentCount": 128,
    "primaryOutcomeMeasure": "LAG-3 expression/immune checkpoint preotein expression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Planned neoadjuvant chemotherapy\n* Triple negative breast cancer\n\nExclusion Criteria:\n\n* HER2-positive breast cancer\n* Hormone receptor positive breast cancer",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}